Eckert & Ziegler SE/€EUZ
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Eckert & Ziegler SE
Eckert & Ziegler SE is a company operating in the pharmaceuticals industry, particularly specializing in the field of medical technology. It focuses on the development, production, and distribution of radioisotopes used for medical imaging, cancer treatment, and industrial applications. Some of its key products include low and high-energy sources used in brachytherapy and calibration sources for imaging devices. Founded in 1997, the company is headquartered in Berlin, Germany. Eckert & Ziegler SE leverages its technical expertise and regulatory experience to deliver specialized solutions, positioning itself as a critical provider in the healthcare and radiation therapy sectors.
- Ticker
- €EUZ
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 1,105
- Headquarters
- Berlin, Germany
- Website
- www.ezag.com
EUZ Metrics
BasicAdvanced
€832M
16.71
€0.79
1.47
€0.22
1.66%
Price and volume
Market cap
€832M
Beta
1.47
52-week high
€17.48
52-week low
€12.01
Average daily volume
100K
Dividend rate
€0.22
Financial strength
Current ratio
3.481
Quick ratio
2.649
Long term debt to equity
0.116
Total debt to equity
0.152
Dividend payout ratio (TTM)
27.68%
Interest coverage (TTM)
16.33%
Profitability
EBITDA (TTM)
88.662
Gross margin (TTM)
48.72%
Net profit margin (TTM)
15.92%
Operating margin (TTM)
24.07%
Effective tax rate (TTM)
31.34%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
10.30%
Return on equity (TTM)
20.14%
Valuation
Price to earnings (TTM)
16.715
Price to revenue (TTM)
2.66
Price to book
3.09
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
35.051
Free cash flow yield (TTM)
2.85%
Free cash flow per share (TTM)
0.379
Dividend yield (TTM)
1.66%
Forward dividend yield
1.66%
Growth
Revenue change (TTM)
4.42%
Earnings per share change (TTM)
36.42%
3-year revenue growth (CAGR)
10.31%
10-year revenue growth (CAGR)
9.01%
3-year earnings per share growth (CAGR)
24.41%
10-year earnings per share growth (CAGR)
20.03%
3-year dividend per share growth (CAGR)
9.69%
10-year dividend per share growth (CAGR)
15.97%
What the Analysts think about EUZ
Analyst ratings (Buy, Hold, Sell) for Eckert & Ziegler SE stock.
Analyst projections of the future price of Eckert & Ziegler SE stock.
Bulls say / Bears say
Medical adjusted EBIT rose nearly 7% in H1, while Lu-177 sales more than tripled and CDMO revenue nearly doubled. That points to growing demand in the higher-growth radiopharmaceutical business. (EQS News, GoingPublic.de)
The new China site is due to start Ge-68 production in early 2027, serving the local market for medical isotopes. A planned second phase could add commercial Ac-225 production, giving the joint venture further growth potential. (EQS News)
A new supply agreement with TerThera adds GMP-grade Tb-161 to Eckert & Ziegler Brazil’s offering. This could help the company participate in emerging radioligand therapies and broaden its reach with regional developers. (TerThera)
H1 sales were almost unchanged and adjusted EBIT fell nearly 6%. The prior-year period included €5 million of licensing revenue, but the company still needs stronger second-half delivery to meet its 2026 targets. (EQS News)
Isotope Products’ H1 adjusted EBIT dropped 24% despite broadly flat sales, as the mix shifted towards lower-margin products. Continued weakness in this segment could offset progress in Medical. (Stock Analysis)
Operating cash flow fell to €12.8 million in H1, and around €9.8 million of investment spending left only about €3 million of free cash flow. Weak cash conversion could constrain the funding flexibility needed for the company’s expansion programme. (GoingPublic.de)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
EUZ Financial Performance
Revenues and expenses
EUZ Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing EUZ
AllEURUSDGBP
Fund name | Fund size | €EUZ weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 0.43% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.07% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.07% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.07% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.